Eganelisib: Phosphatidylinositol 3-kinase γ (PI3Kγ) inhibitor Treatment of triple-negative breast cancer

L. Bo, Y. K. Zhang, S. E. Reznik, Z. S. Chen

Research output: Contribution to journalArticlepeer-review


Triple-negative breast cancer (TNBC) is a subtype of breast cancer deficient in estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (HER2) expression. Due to these genetic mutations, its invasive nature and relatively poor response to drug therapy, TNBC remains a challenging clinical problem. Phosphoinositide-3-kinase γ (PI3Kγ) plays a critical role in the regulation between immune stimulation and suppression in inflammation and cancer. Eganelisib is an immuno-oncology drug candidate that can selectively inhibit PI3Kγ and hinders the PI3K/AKT/mTOR signaling pathways. This article summarizes the characteristics and current treatment options for TNBC. We also present innovative multidrug combination systemic therapies for TNBC, which have been tested in preclinical and clinical studies using eganelisib.

Original languageEnglish (US)
Pages (from-to)963-975
Number of pages13
JournalDrugs of the Future
Issue number12
StatePublished - Dec 2021


  • Eganelisib
  • IPI-549
  • Immunotherapy
  • Multidrug resistance
  • PI3Kγ
  • Phosphoinositide-3-kinase γ
  • Triple-negative breast cancer

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Eganelisib: Phosphatidylinositol 3-kinase γ (PI3Kγ) inhibitor Treatment of triple-negative breast cancer'. Together they form a unique fingerprint.

Cite this